|
【结 构 式】 
|
【分子编号】56229 【品名】(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-9-{[(allyloxy)carbonyl]oxy}-15-{[(2R,3S)-2-{[(allyloxy)carbonyl]oxy}-3-(benzoylamino)-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0~3,10~.0~4,7~]heptadec-13-en-2-yl benzoate 【CA登记号】 |
【 分 子 式 】C55H59NO18 【 分 子 量 】1022.0694 【元素组成】C 64.63% H 5.82% N 1.37% O 28.18% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(VI)In an alternative method, paclitaxel (I) was acylated with allyl chloroformate (V) to afford the bis-carbonate (VI). Dihydroxylation of both allyl groups of (VI) was accomplished by treatment with tert-butyl hydroperoxide producing (IV). The 2'-ester of (IV) was finally removed upon stirring in a NaHCO3-neutralized solution at room temperature.
| 【1】 Seligson, A.L.; et al.; A new prodrug of paclitaxel: Synthesis of Protaxel. Anti-Cancer Drugs 2001, 12, 4, 305. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 10595 | (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetoxy)-15-[[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy]-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate | 33069-62-4 | C47H51NO14 | 详情 | 详情 |
| (IV) | 56228 | (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-[((2R,3S)-3-(benzoylamino)-2-{[(2,3-dihydroxypropoxy)carbonyl]oxy}-3-phenylpropanoyl)oxy]-9-{[(2,3-dihydroxypropoxy)carbonyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0~3,10~.0~4,7~]heptadec-13-en-2-yl benzoate | C55H63NO22 | 详情 | 详情 | |
| (V) | 38115 | 3-[(chlorocarbonyl)oxy]-1-propene | 2937-50-0 | C4H5ClO2 | 详情 | 详情 |
| (VI) | 56229 | (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-9-{[(allyloxy)carbonyl]oxy}-15-{[(2R,3S)-2-{[(allyloxy)carbonyl]oxy}-3-(benzoylamino)-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0~3,10~.0~4,7~]heptadec-13-en-2-yl benzoate | C55H59NO18 | 详情 | 详情 |
Extended Information